Quantum BioPharma is trading 10.78% up at $3.78 after a broad biotech-sector rally following positive Moderna and Merck Phase 3 melanoma-vaccine results.
- The trial met its primary recurrence-free-survival endpoint and a key distant-metastasis endpoint, lifting sentiment toward biotechnology and mRNA drug development.
- The move recovers part of Quantum BioPharma’s 9.24% decline on August 18.
- No fresh company-specific catalyst was identified for August 19.